Adi Zuloff-Shani
Chief Executive Officer chez CLEARMIND MEDICINE INC.
Fortune : 1 929 $ au 31/03/2024
Profil
Adi Zuloff-Shani is currently the Chief Executive Officer at Clearmind Medicine, Inc., Chairman at Orsus Therapeutics Plc, Director at MitoCareX Bio Ltd., and Chief Technology Officer at SciSparc Ltd.
Previously, Adi held the position of Vice President-Development at Macrocure Ltd.
Adi's education includes undergraduate and doctorate degrees from Bar-Ilan University.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
CLEARMIND MEDICINE INC.
0,05% | 31/10/2023 | 1 667 ( 0,05% ) | 1 917 $ | 31/03/2024 |
SCISPARC LTD.
0,00% | 24/04/2023 | 7 ( 0,00% ) | 12 $ | 31/03/2024 |
Postes actifs de Adi Zuloff-Shani
Sociétés | Poste | Début |
---|---|---|
SCISPARC LTD. | Chief Tech/Sci/R&D Officer | 08/02/2016 |
CLEARMIND MEDICINE INC. | Chief Executive Officer | 14/07/2021 |
Orsus Therapeutics Plc | Chairman | 01/11/2021 |
Anciens postes connus de Adi Zuloff-Shani
Sociétés | Poste | Fin |
---|---|---|
MACROCURE LTD | Corporate Officer/Principal | 01/01/2016 |
Formation de Adi Zuloff-Shani
Bar-Ilan University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
SCISPARC LTD. | Health Technology |
CLEARMIND MEDICINE INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Macrocure Ltd.
Macrocure Ltd. Medical SpecialtiesHealth Technology Macrocure Ltd. is a clinical-stage biotechnology company, which engages in the development and commercialization of advanced cell therapy products. Its product, CureXcell, is an advanced wound care therapy that treat such wounds by injecting living human white blood cells that have been activate to facilitate the healing process. The company was founded by David Ben-Ami on January 14, 2008 and is headquartered in Petach Tikva, Israel. | Health Technology |
Orsus Therapeutics Plc |